Genzyme files for Quick Tack approval:
This article was originally published in Clinica
Executive Summary
Genzyme Tissue Repair has submitted a 510(k) application to the US FDA to market its Quick Tack periosteal fixation system. The device is used instead of sutures during the implantation of the company's Carticel autologous cultured chondrocyte product, which is used to repair cartilage damage to the knee. Implantation of the Carticel product is currently an open-knee procedure, and the company sees Quick Tack as a first step towards arthroscopic placement.